IPV疫苗

Search documents
科兴集团尹卫东:生物技术叠加AI革命,重塑健康诉求释放机遇
Bei Ke Cai Jing· 2025-08-29 14:47
Core Insights - The biopharmaceutical industry is currently experiencing four major patterns that open new development spaces for the entire sector [1] - The pandemic has accelerated the application of biotechnology, creating significant health market demand [1] - The integration of biotechnology with AI technology is reshaping health demands and releasing substantial growth opportunities [1] - China's biopharmaceutical industry is focusing on global strategies, leveraging its 1.4 billion domestic market to expand internationally [1] Group 1 - The four major patterns identified by the company include the pandemic's impact, technological integration, industry challenges, and the need for global strategies [1] - The company aims to provide "global solutions" for human health by offering the best services and technology products, meeting new health demands, and ensuring high-quality standards [1] Group 2 - The event marked the first external activity since the opening of the Kexing Laifucheng Park, highlighting its significance as a key project in Beijing [2] - The company proposed four initiatives to enhance collaboration with supply chain partners, focusing on breaking boundaries, innovation, upgrading cooperation, and maintaining high quality [2] - The company has achieved significant results through collaboration, including the application of advanced technologies in various products and successful international market expansion [2]
科兴集团与69家企业探讨产业链上下游协作创新
Zheng Quan Ri Bao Wang· 2025-08-29 13:41
Core Viewpoint - The 2025 Supply Chain Ecological Conference hosted by Beijing Kexing Holdings Group aims to foster collaboration and innovation within the biopharmaceutical industry, highlighting the potential opportunities amidst uncertainties in the sector [1][2] Group 1: Industry Insights - The biopharmaceutical industry is currently characterized by four major patterns that open new development spaces for the sector [1] - The true path for China's biopharmaceutical industry is to provide "global solutions" for human health, focusing on high-quality standards, affordability, and accessibility [1] Group 2: Company Initiatives - Kexing Group has achieved significant innovations in collaboration with partners, including the application of cell factories and disposable systems in various products such as hepatitis A, IPV, and COVID-19 vaccines [2] - The company has also responded to WHO pre-certification requirements by being among the first in China to apply the PUPSIT system for product sterilization filtration [2] - Kexing Group has successfully expanded into international markets, exemplified by its partnership in Turkey, where it supplies syringes and packaging equipment alongside its vaccines [2] Group 3: Conference Highlights - The conference featured 14 companies showcasing cutting-edge products and innovations in areas such as biological raw materials, laboratory equipment, and quality control solutions [2]